TCM
OREX

Tamarack Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Tamarack Capital Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-100,000
Closed -$7.83M – 47
2015
Q1 		$7.83M Buy
+100,000
New +$6.2M 1.03% 27

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Tamarack Capital Management's OREX Position: Q2 2015 in Review

Tamarack Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 100,000 shares — an estimated $7.83M sold.

Tamarack Capital Management first reported a position in OREX in Q1 2015 and held it in 1 quarter. The position peaked at $7.83M in Q1 2015. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

  • Tamarack Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Tamarack Capital Management sold 100,000 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $7.83M.
  • Tamarack Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Tamarack Capital Management's Orexigen Therapeutics, Inc. position peaked at $7.83M in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on Tamarack Capital Management's 13F filing for Q2 2015, filed 11 Aug 2015.